Literature DB >> 35845563

A Preliminary, Single-Center Retrospective Chart Review of Infusion Times of Intravenous Immune Globulin in Kawasaki Disease and Clinical Outcomes.

Joseph P Griffin1, Angela R Powell1, Palak H Bhagat2, Allison H Bartlett3, Shannon M Rotolo2.   

Abstract

OBJECTIVE: Patients diagnosed with Kawasaki disease (KD) are at a high risk of developing coronary artery aneurysms. Intravenous immune globulin (IVIG) given in combination with aspirin is the standard of treatment for the prevention of coronary aneurysm. IVIG is recommended to be administered as a dose of 2 g/kg infused during 10 to 12 hours for the prevention of coronary aneurysms in KD; however, this does not always occur in practice. We aimed to investigate if an infusion time of <10 hours is associated with more coronary artery aneurysms than the recommended infusion time of 10 to 12 hours.
METHODS: Patients with a diagnosis of and treated for KD with IVIG at the University of Chicago Medicine Comer Children's Hospital were identified by drug use reports that included patients who received IVIG between September 2008 and August 2018. Data were collected though chart review and patients were divided into 2 groups based on duration of infusion (<10 hours and 10-12 hours). The primary outcome was the incidence of coronary artery aneurysm. The secondary outcome was the time to defervescence. The safety outcome was the development of renal dysfunction.
RESULTS: A total of 70 patients were screened and 44 were included in the analysis. Coronary aneurysm occurred in 2 of 33 patients (6.0%) in the <10-hour group and no patients in the 10- to 12-hour group (p = 0.558). The median time to defervescence was 0.5 hours in the <10-hour group and 0.95 hours in the 10- to 12-hour group (p = 0.166). The incidence of acute kidney injury was 6% (2 of 33 patients) in the 10-hour group and 9.1% (1 of 11 patients) in the 10- to 12-hour group (p = 0.588).
CONCLUSIONS: All incidences of coronary artery aneurysm occurred in the patients who received IVIG with an infusion time of <10 hours. The incidence of acute kidney injury was numerically higher in the 10- to 12-hour group. Based on the recommendations in the American Heart Association KD guideline, our internal hospital policy, and our results, we recommend the infusion of IVIG be administered at a rate of 10 to 12 hours. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.

Entities:  

Keywords:  Kawasaki disease; coronary aneurysm; guideline adherence; immunoglobulins; infusion time; intravenous

Year:  2022        PMID: 35845563      PMCID: PMC9268116          DOI: 10.5863/1551-6776-27.5.415

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  5 in total

1.  Pediatric Risk, Injury, Failure, Loss, End-Stage renal disease score identifies acute kidney injury and predicts mortality in critically ill children: a prospective study.

Authors:  Yadira A Soler; Mariely Nieves-Plaza; Mónica Prieto; Ricardo García-De Jesús; Marta Suárez-Rivera
Journal:  Pediatr Crit Care Med       Date:  2013-05       Impact factor: 3.624

2.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

3.  Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin.

Authors:  K S Barron; D J Murphy; E D Silverman; H D Ruttenberg; G B Wright; W Franklin; S J Goldberg; S M Higashino; D G Cox; M Lee
Journal:  J Pediatr       Date:  1990-10       Impact factor: 4.406

Review 4.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

5.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Authors:  J W Newburger; M Takahashi; A S Beiser; J C Burns; J Bastian; K J Chung; S D Colan; C E Duffy; D R Fulton; M P Glode
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

  5 in total
  1 in total

Review 1.  Neutrophil to Lymphocyte Ratio as a Biomarker for Predicting the Coronary Artery Abnormality in Kawasaki Disease: A Meta-Analysis.

Authors:  Shirin Sarejloo; Matin Moallem Shahri; Pouria Azami; Alec Clark; Ethan Hass; Maryam Salimi; Brandon Lucke-Wold; Shahram Sadeghvand; Shokoufeh Khanzadeh
Journal:  Dis Markers       Date:  2022-10-11       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.